Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this early-stage clinical study is to demonstrate an effect of
single doses of CK-2017357 on measures of skeletal muscle function and fatigability in
patients with generalized myasthenia gravis (MG).
Phase:
Phase 2
Details
Lead Sponsor:
Cytokinetics
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)